Sirius Therapeutics, Inc.
PrivateLast Round
Series B
Extension
May 9, 2025
Est. Valuation
$253M
Total Funding Raised
$207.5M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Sirius Therapeutics, Inc. is a biotechnology company developing innovative siRNA therapies for global markets, focusing on cardiovascular and chronic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Sirius Therapeutics, Inc. Comparables
Compare Sirius Therapeutics, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| ADARx Pharmaceuticals | 86% | |
| Argo Biopharma | 84% | |
| Rona Therapeutics | 83% |
Sirius Therapeutics, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | May 9, 2025 | ||||
| Series B | Oct 9, 2023 | ||||
| Series B | Sep 1, 2023 | ||||
| Series A | Jul 13, 2022 |
Sirius Therapeutics, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| BioTrack Capital | Series B Extension |
| Creacion Ventures | Series B, Series B Extension, Series A |
| OrbiMed | Series B, Series B Extension, Series A |
| Hankang Capital | Series B Extension, Series B |
| Delos Capital Partners | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 27, 2026
Grew 29% QoQ, from 14 to 18 employees.
- Apr 27, 2026
Grew 38% QoQ, from 13 to 18 employees.
Sirius Therapeutics, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Sirius Therapeutics, Inc.'s valuation, stock price, and market status.
Is Sirius Therapeutics, Inc. a public or private company?
Sirius Therapeutics, Inc. is a private company.
What is the current stock price of Sirius Therapeutics, Inc.?
Sirius Therapeutics, Inc. is a private company with no public stock price. No recent secondary market data is available.
How much is Sirius Therapeutics, Inc. worth (valuation)?
Sirius Therapeutics, Inc.'s valuation is estimated at $253.0M based on funding round data.
Can I buy Sirius Therapeutics, Inc. stock?
Sirius Therapeutics, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Sirius Therapeutics, Inc.'s last funding round?
Sirius Therapeutics, Inc.'s most recent funding round was Series B Extension on May 9, 2025.
Who are the main investors in Sirius Therapeutics, Inc.?
Key investors in Sirius Therapeutics, Inc. include Hankang Capital.
Will Sirius Therapeutics, Inc. IPO soon?
No public IPO plans have been announced for Sirius Therapeutics, Inc..
How can I track Sirius Therapeutics, Inc. secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Sirius Therapeutics, Inc.'s secondary market activity and sign up for updates.